Bristol Myers Squibb (BMY)

[chmcnfunds]

Bristol-Myers' Lirilumab Flunks Mid-Stage Study In Leukemia

Feb. 6, 2017 7:15 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

A Phase 2 clinical trial, EffiKIR, assessing Bristol-Myers Squibb's (NYSE:BMY) lirilumab as monotherapy for the maintenance treatment of elderly patients with acute myeloid leukemia (AML) in its first complete remission failed to achieve its primary endpoint of leukemia-free survival (LFS).

There were no significant differences in LFS or any other efficacy endpoints in either arm of the study between the test groups and placebo. One treatment arm, 1 mg/kg once per month, was discontinued in March 2015 based on the recommendation from the Data Safety Monitoring Board (DSMD). The data analysis in ongoing. Complete results will be presented at a future medical conference.

Bristol is investigating lirilumab in six studies in a range of solid tumors and blood cancers.

Lirilumab is a fully human monoclonal antibody that is designed to help the immune system attack tumors by acting as a checkpoint inhibitor by blocking the interaction between inhibitory receptors called KIR2DL-1, -2 and -3 and their ligands.

Bristol-Myers licensed lirilumab from Innate Pharma (OTCPK:IPHYF) in 2014.

BMY is up a fraction premarket.
_____________________________________
http://seekingalpha.com/news/3240687-bristol-myers-lirilumab-flunks-mid-stage-study-leukemia?app=1&uprof=46#email_link

BMY